Honasa Consumer acquired a majority 58% stake in nutraceuticals company Fluence Pharma for ₹135 crore. This pushes the Mamaearth parent into a new vertical via a company that reported just ₹37.2 crore in FY25 turnover. Honasa is setting up a new subsidiary, Honasa Health, specifically to build end-to-end B2C operations in this space.
How We Got Here
This acquisition aligns with Honasa's "Honasa 3.0" strategy, unveiled at its investor day earlier this month. Under this five-year roadmap, the company targets doubling its FY31 revenue to over ₹5,500 crore and expanding its offline footprint to over 3 lakh outlets.
The Numbers
- Fluence Pharma was founded in 2012 by Amit Bhusari and Dr Rajendra Singh Rajput.
- Fluence distributes its skin and hair health supplements through a network of over 3,000 dermatologists and trichologists.
- The company offers condition-specific OTC supplement kits built on patented Cyclical Nutrition Therapy (CNT).
- Honasa plans to acquire the remaining 42% of Fluence equity in two tranches over the next 5-7 years.
- CEO Varun Alagh estimates India’s nutraceuticals market valuation at ₹16,000 crore, driving Honasa’s entry.
What Happens Next
🇮🇳 Why This Matters for India
For product managers building D2C health and wellness brands in Hyderabad, this acquisition signals a new front where marketing strength meets specialized clinical distribution for the ₹16,000 crore nutraceuticals sector.
The Take
Honasa is paying a premium for Fluence's clinical distribution, not just its existing revenue. The real play here is Honasa trying to bridge mass-market D2C with credible doctor-led channels, sidestepping the trust deficit many nutraceutical brands face.
Source:
Inc42 ↗